<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rationale: Diabetic <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> is common and causes significant morbidity </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002870'>Obstructive sleep apnea</z:hpo> (OSA) is also common in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Because OSA is associated with <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0003674'>oxidative stress</z:mp>, we hypothesized that OSA is associated with <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Objectives: To assess the relationship between OSA and <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Methods: A cross-sectional study of adults with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> recruited randomly from the <z:mp ids='MP_0002055'>diabetes</z:mp> clinic of two UK hospitals </plain></SENT>
<SENT sid="5" pm="."><plain>Measurements and Main Results: <z:hpo ids='HP_0009830'>Peripheral neuropathy</z:hpo> was diagnosed using the Michigan <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> Screening Instrument </plain></SENT>
<SENT sid="6" pm="."><plain>OSA (<z:hpo ids='HP_0002104'>apnea</z:hpo>-<z:mp ids='MP_0001956'>hypopnea</z:mp> index â‰¥ 5 events/h) was assessed using home-based, multichannel respiratory monitoring </plain></SENT>
<SENT sid="7" pm="."><plain>Serum nitrotyrosine was measured by ELISA, <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="39" ids="44785">peroxide</z:chebi> by spectrophotometer, and microvascular function by laser speckle contrast imaging </plain></SENT>
<SENT sid="8" pm="."><plain>Two hundred thirty-four patients (mean [SD] age, 57 [12] yr) were analyzed </plain></SENT>
<SENT sid="9" pm="."><plain>OSA prevalence was 65% (median <z:hpo ids='HP_0002104'>apnea</z:hpo>-<z:mp ids='MP_0001956'>hypopnea</z:mp> index, 7.2; range, 0-93), 40% of which were moderate to severe </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> prevalence was higher in patients with OSA than those without (60% vs. 27%, P &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>After adjustment for possible confounders, OSA remained independently associated with <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> (odds ratio, 2.82; 95% confidence interval, 1.44-5.52; P = 0.0034) </plain></SENT>
<SENT sid="12" pm="."><plain>Nitrotyrosine and <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="39" ids="44785">peroxide</z:chebi> levels (n = 102, 74 with OSA) were higher in OSA and correlated with hypoxemia severity </plain></SENT>
<SENT sid="13" pm="."><plain>Cutaneous microvascular function (n = 71, 47 with OSA) was impaired in OSA </plain></SENT>
<SENT sid="14" pm="."><plain>Conclusions: We describe a novel independent association between diabetic <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> and OSA </plain></SENT>
<SENT sid="15" pm="."><plain>We identified increased nitrosative/<z:mp ids='MP_0003674'>oxidative stress</z:mp> and impaired microvascular regulation as potential mechanisms </plain></SENT>
<SENT sid="16" pm="."><plain>Prospective and interventional studies are needed to assess the impact of OSA and its treatment on <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> development and progression in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>